A reappraisal of loop diuretic choice in heart failure patients

被引:85
作者
Buggey, Jonathan [1 ]
Mentz, Robert J. [1 ,2 ]
Pitt, Bertram [3 ]
Eisenstein, Eric L. [2 ]
Anstrom, Kevin J. [2 ]
Velazquez, Eric J. [1 ,2 ]
O'Connor, Christopher M. [1 ,2 ]
机构
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] Univ Michigan Hlth Syst, Ann Arbor, MI USA
关键词
ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE CARDIAC-FAILURE; TRANSCARDIAC EXTRACTION; FUROSEMIDE ABSORPTION; RANDOMIZED TRIAL; TORASEMIDE; TORSEMIDE; ALDOSTERONE; PHARMACOKINETICS; SPIRONOLACTONE;
D O I
10.1016/j.ahj.2014.12.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The health and economic burden of heart failure is significant and continues to grow each year. Loop diuretics are an integral part of symptom management in heart failure. Furosemide is used disproportionately compared with other loop diuretics, and there is currently no guidance for physicians regarding which agent to choose. However, there exist pharmacologic differences as well as other mechanistic differences that appear to favor torsemide use over furosemide. Compared with furosemide, torsemide improves surrogate markers of heart failure severity such as left ventricular function, plasma brain natriuretic peptide levels, and New York Heart Association functional class and may also reduce hospitalizations, readmissions, and mortality. Data suggest that these benefits could be mediated through torsemide's ability to positively affect the renin-angiotensin-aldosterone system. Specifically, torsemide has been shown to inhibit aldosterone secretion, synthesis, and receptor binding in vitro, as well as decrease transcardiac extraction of aldosterone, myocardial collagen production, and cardiac fibrosis in patients with heart failure. We identified pertinent literature using keyword MEDLINE searches and cross-referencing prior bibliographies. We summarize the available data suggesting potential benefits with torsemide over furosemide, and call attention to the need for a reappraisal of diuretic use in heart failure patients and also for a well-powered, randomized control trial assessing torsemide versus furosemide use.
引用
收藏
页码:323 / 333
页数:11
相关论文
共 68 条
[1]   Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000, cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J].
Adams, KF ;
Fonarow, GC ;
Emerman, CL ;
LeJemtel, TH ;
Costanzo, MR ;
Abraham, WT ;
Berkowitz, RL ;
Galvao, M ;
Horton, DP .
AMERICAN HEART JOURNAL, 2005, 149 (02) :209-216
[2]   Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial [J].
Ambrosy, Andrew P. ;
Pang, Peter S. ;
Khan, Sadiya ;
Konstam, Marvin A. ;
Fonarow, Gregg C. ;
Traver, Brian ;
Maggioni, Aldo P. ;
Cook, Thomas ;
Swedberg, Karl ;
Burnett, John C., Jr. ;
Grinfeld, Liliana ;
Udelson, James E. ;
Zannad, Faiez ;
Gheorghiade, Mihai .
EUROPEAN HEART JOURNAL, 2013, 34 (11) :835-843
[3]   EFFECTS OF ADDING SPIRONOLACTONE TO AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR IN CHRONIC CONGESTIVE-HEART-FAILURE SECONDARY TO CORONARY-ARTERY DISEASE [J].
BARR, CS ;
LANG, CC ;
HANSON, J ;
ARNOTT, M ;
KENNEDY, N ;
STRUTHERS, AD .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (17) :1259-1265
[4]  
BAYLISS J, 1987, BRIT HEART J, V57, P17
[5]   Dominance of Furosemide for Loop Diuretic Therapy in Heart Failure Time to Revisit the Alternatives? [J].
Bikdeli, Behnood ;
Strait, Kelly M. ;
Dharmarajan, Kumar ;
Partovian, Chohreh ;
Coca, Steven G. ;
Kim, Nancy ;
Li, Shu-Xia ;
Testani, Jeffrey M. ;
Khan, Usman ;
Krumholz, Harlan M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (14) :1549-1550
[6]   Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure [J].
Bleske, BE ;
Welage, LS ;
Kramer, WG ;
Nicklas, JM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (08) :708-714
[7]   BUMETANIDE AND FUROSEMIDE IN HEART-FAILURE [J].
BRATER, DC ;
DAY, B ;
BURDETTE, A ;
ANDERSON, S .
KIDNEY INTERNATIONAL, 1984, 26 (02) :183-189
[8]   TORASEMIDE, A NEW POTENT DIURETIC - DOUBLE-BLIND COMPARISON WITH FUROSEMIDE [J].
BROEKHUYSEN, J ;
DEGER, F ;
DOUCHAMPS, J ;
DUCARNE, H ;
HERCHUELZ, A .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 :29-34
[9]   Torasemide in chronic heart failure:: results of the TORIC study [J].
Cosín, J ;
Díez, J .
EUROPEAN JOURNAL OF HEART FAILURE, 2002, 4 (04) :507-513
[10]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003